Document is current

Article History

Received: 1 April 2020

Accepted: 3 September 2020

First Online: 11 November 2020

Competing interests

: A.K. is on the advisory board and/or speakers bureau for AstraZeneca, Behring, Boehringer Ingelheim, Covis, Grifols, GSK, Merck Frosst, Novartis, Novo Nordisk, Pfizer, Purdue, Sanofi, Teva and Trudell; and is a member of Health Canada Section on Allergy and Respiratory Therapeutics; co-chair of Ontario Health Quality, Ontario Quality Standards for COPD; member of Ontario Health Quality, Ontario Quality Standards Asthma Chairperson, Family Physician Airways Group of Canada; honorary professor of Respiratory Medicine of the Observational and Pragmatic Research, Singapore; vice president of the Respiratory Effectiveness Group and medical lead at Lung Health Portal, MD Briefcase. J.M.F. is on the advisory board and/or speakers bureau for AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Regeneron, Sanofi and Theravance; receives peer-review funding from AllerGen, NIH, and CIHR; research funding from AstraZeneca, GSK, Novartis and Sanofi-Regeneron, all paid directly to UBC; is a member of the steering committee for the International Severe Asthma Registry and PI for Canadian Severe Asthma Registry and is a member of the GINA Science and Executive Committees. R.B. reports grants to Mainz University and personal fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis and Roche, as well as personal fees from AstraZeneca, Chiesi, Cipla, Sanofi and Teva, and is a member of the GINA Science Committee. C.V. is on the advisory board and/or speakers bureau for ALK, AllergoPharma, Bencard, Boehringer Ingelheim, DBV Technology, HAL Allergy, Novartis and Sanofi; is President of the Society of Pediatric Allergology and Environmental Medicine (GPA); he is co-author of the German National Management Guideline for Asthma (NVL Asthma) and he is receiving grants from the German Research Foundation (DFG). E.H. is on the advisory board and/or speakers bureau for ALK, AllergoPharma, Bencard, Boehringer Ingelheim, GSK, Novartis, Nutricia, Sanofi and Stallergenes; is President of the German Asthma Net (GAN) e.V., Vice-President of the German Allergy Society (DGAKI) and co-chair of the asthma section of the German Pediatric Pneumology Society (GPP); he is coordinator of the German guideline for severe asthma in children and co-author of the German National Management Guideline for Asthma (NVL Asthma) and he is receiving grants from the German Ministry of Education and Research (BMBF).